Literature DB >> 15885624

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

C Guigoni1, I Aubert, Q Li, V V Gurevich, J L Benovic, S Ferry, U Mach, H Stark, L Leriche, K Håkansson, Bernard H Bioulac, Christian E Gross, Pierre Sokoloff, Gilberto Fisone, E V Gurevich, Bertrand Bloch, Erwan Bezard.   

Abstract

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease. Taking advantage of a monkey brain bank constituted to study the pathophysiology of levodopa-induced dyskinesia, we here report the changes affecting D1, D2 and D3 dopamine receptors within the striatum of four experimental groups of non-human primates: normal, parkinsonian, parkinsonian treated with levodopa without or with dyskinesia. We also report the possible role of arrestin and G protein-coupled receptor kinases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885624     DOI: 10.1016/j.parkreldis.2004.11.005

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  43 in total

Review 1.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

2.  Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.

Authors:  Roberta Marongiu; Margarita Arango-Lievano; Veronica Francardo; Peter Morgenstern; Xiaoqun Zhang; M Angela Cenci; Per Svenningsson; Paul Greengard; Michael G Kaplitt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 3.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

4.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay Riddle; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

5.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

Review 6.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

7.  Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.

Authors:  Zhude Tu; Shihong Li; Jinbin Xu; Wenhua Chu; Lynne A Jones; Robert R Luedtke; Robert H Mach
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

Review 8.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

9.  Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.

Authors:  Oscar Solís; Jose Ruben Garcia-Montes; Aldo González-Granillo; Ming Xu; Rosario Moratalla
Journal:  Cereb Cortex       Date:  2017-01-01       Impact factor: 5.357

10.  The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway.

Authors:  Salvatore Galati; Paolo Stanzione; Vincenza D'Angelo; Ernesto Fedele; Francesco Marzetti; Giuseppe Sancesario; Teresa Procopio; Alessandro Stefani
Journal:  J Physiol       Date:  2009-07-21       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.